123 related articles for article (PubMed ID: 38289887)
21. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.
Lalan S; Abdel-Rahman S; Gaedigk A; Leeder JS; Warady BA; Dai H; Blowey D
Pediatr Nephrol; 2014 Oct; 29(10):2039-49. PubMed ID: 24875272
[TBL] [Abstract][Full Text] [Related]
22. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
Lesche D; Sigurdardottir V; Setoud R; Oberhänsli M; Carrel T; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
[TBL] [Abstract][Full Text] [Related]
23. CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.
Krall P; Yañez D; Rojo A; Delucchi Á; Córdova M; Morales J; Boza P; de la Rivera A; Espinoza N; Armijo N; Castañeda LE; Farfán MJ; Salas C
Front Pharmacol; 2021; 12():653525. PubMed ID: 33967795
[No Abstract] [Full Text] [Related]
24. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
25. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
26. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
Shilbayeh S; Zmeili R; Almardini RI
Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1125-36. PubMed ID: 24231473
[TBL] [Abstract][Full Text] [Related]
27. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
[TBL] [Abstract][Full Text] [Related]
28. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
29. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
[TBL] [Abstract][Full Text] [Related]
30. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
31. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
32. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
33. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
[TBL] [Abstract][Full Text] [Related]
34. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.
Everton JBF; Patrício FJB; Faria MS; Ferreira TCA; Romao EA; Silva GEB; Magalhães M
Eur J Clin Pharmacol; 2021 Jun; 77(6):879-886. PubMed ID: 33398393
[TBL] [Abstract][Full Text] [Related]
35. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
[TBL] [Abstract][Full Text] [Related]
36. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
37. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
Wanas H; Kamel MH; William EA; Fayad T; Abdelfattah ME; Elbadawy HM; Mikhael ES
J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
[TBL] [Abstract][Full Text] [Related]
38. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
[TBL] [Abstract][Full Text] [Related]
39. Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation.
Choi JS; Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Kang HG; Ha IS; Min S
Pediatr Transplant; 2022 Sep; 26(6):e14297. PubMed ID: 35466485
[TBL] [Abstract][Full Text] [Related]
40. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
